Inivata’s RaDaR Assay for Molecular Residual Disease Earns CE Mark

Cambridge, UK-based Inivata has received a CE mark for its RaDaR assay for the detection of residual disease in cancer patients.

The liquid biopsy assay can detect circulating cancer DNA from up to 48 tumor-specific variants from a single blood sample, according to Inivata, a subsidiary of Fort Myers, Fla.-based NeoGenomics Laboratories.

The diagnostic test has demonstrated 95 percent sensitivity and 100 percent specificity for detecting tumor DNA concentration levels as low as 11 parts per million, the company said.